Human IFI35 Knockout A549 Cell Line

Cat. No.
CLCP-00350177
Product Size
1 x 106 cells/vial, 1 mL

Product Overview

Parental Cell Line
A549
Biosafety Level
BSL-1
Species
Human
Mutation Description
Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 3 and 1 bp insertion in exon 3
Knockout Validation
Sanger Sequencing

Cell Line Properties

Tissue
Lung carcinoma
Morphology
Epithelial
Viability
~80%
Adherent / Suspension
Adherent
Gender
Male

Target Information

Gene Name
IFI35
Gene ID
UniProt No.
Gene Function
Acts as a signaling pathway regulator involved in innate immune system response. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation. In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production. In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion. Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines.
Sequence Similarities
Belongs to the NMI family.

Storage & Handling

Recommended Control
Human wild-type A549 cell line.
Cryopreservation Cell Medium
Cell freezing medium - DMSO serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Culture Medium
F-12K + 10% FBS
Initial Handling Guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80 °C. Storage at -80 °C may result in loss of viability.
Storage Instructions
Shipped on dry ice. Store in liquid nitrogen.
Storage Buffer
Constituents: 8.7% Dimethylsulfoxide, 2% Cellulose, methyl ether.

For Research Use Only. Not For Clinical Use.

Online Inquiry